#OpenAI

#OpenAI

“You didn't disclose to the United States Senate that you had an interest in OpenAI through a share in a Y Combinator fund, did you?” barked Steve Molo, the combative attorney leading Elon Musk's effort to shut down OpenAI's for-profit business. Altman had admitted that he did have economic exposure to OpenAI through his LP position in the Y Combinator fund. “I didn't mention it in that testimony, but, again, I think it is well understood of what it means to be a passive owner of many venture funds,” Almtan said.

The school's endowment invested $20 million in OpenAI during a very early fundraising round, well before Microsoft's $1 billion investment in 2019 and before most people had heard of the AI lab. That stake is now expected to be worth roughly $2 billion, representing a staggering 9,900% return on a single investment.

Leila Turner-Scott and Angus Scott filed a lawsuit against the company, alleging that it designed and distributed a "defective product" that led to the death of their son Sam Nelson from an accidental overdose. Specifically, they're alleging that Sam died following the "exact medical advice GPT-4o had provided and approved."

Musk's lawyers used cross-examination to attack Altman's credibility, citing testimony from former OpenAI figures including Mira Murati, Ilya Sutskever and Helen Toner, along with older criticism from his career as a tech executive and investor. Musk's lawyers also highlighted OpenAI's dealings with companies in which Altman holds a financial stake, including Stripe, Cerebras and Helion.

Musk's attorney, Steven Molo, opened his cross-examination of Altman with the blunt question: "Are you completely trustworthy?" "I believe so," Altman told the federal California jury in the civil trial of Musk's lawsuit against Altman and OpenAI. "You don't know whether you're completely trustworthy?" Molo followed up, forcing Altman to respond, "I'll just amend my answer to yes." Molo then peppered Altman with questions about whether the billionaire chief executive tells the truth, lies to advance his business interests, or misleads the people he works with.

Criteo's leadership assured the markets that it would return to growth by the end of the year, but the immediate result was a slide in its share price based on an even more conservative 2026 revenue forecast.